Jan-Spider

Jan-Spider is a biotechnology company based in Shanghai that specializes in the discovery and development of novel peptide therapeutics derived from spider venom. The company leverages a proprietary high-throughput screening platform and a vast library of spider toxins to identify highly selective modulators of ion channels, particularly voltage-gated sodium channels. Their primary research focus is on developing non-opioid treatments for chronic pain and pruritus by targeting specific subunits like Nav1.7 and Nav1.8. By utilizing the natural evolution of venom peptides, Jan-Spider aims to overcome the selectivity challenges often associated with traditional small molecule ion channel blockers.